Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Immune Checkpoint Inhibitor
•
Pediatric Oncology
How do you determine timing, and whether or not to rechallenge a pediatric oncology patient with immune checkpoint inhibitor therapy after development of irAE?
Related Questions
What is your typical surveillance imaging for a pediatric patient with history of treated sarcoma off therapy?
Which oral chemotherapy regimen do you use in relapsed fusion positive rhabdomyosarcoma?
For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?
How do you approach adjuvant therapy for resected Stage I Ewing sarcoma of the kidney, and what chemotherapy regimen and cycle duration do you recommend?
How would you approach the prevention of irinotecan-induced diarrhea in a patient who previously experienced a diffuse rash with cefixime?
What is your approach to patients/parents seeking alternative or complementary treatment in pediatric oncology patients?
How do you approach the treatment of teen patients with recurrent mediastinal germ cell tumor who have failed standard therapy, radiation, and HD therapy/stem cell rescue?
When do you consider altering treatment for a patient with metastatic osteosarcoma who showed poor response to upfront therapy with MAP (doxorubicin, cisplatin, methotrexate) chemotherapy?
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
Do you routinely use thrombopoietin receptor agonists (like romiplostim) to address chemotherapy-induced thrombocytopenia in solid tumor pediatric oncology patients?
